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Abstract
Severe pulmonary arterial hypertension, whether idiopathic or secondary, is characterized by
structural alterations of microscopically small pulmonary arterioles. The vascular lesions in this
group of pulmonary hypertensive diseases show actively proliferating endothelial cells without
evidence of apoptosis. In this article, we review pathogenetic concepts of severe pulmonary arterial
hypertension and explain the term "complex vascular lesion ", commonly named "plexiform lesion",
with endothelial cell dysfunction, i.e., apoptosis, proliferation, interaction with smooth muscle cells
and transdifferentiation.
Introduction
Severe pulmonary arterial hypertension (PAH), whether
idiopathic or associated with known causes (secondary
forms), may have a reversible component in a minority of
the patients [1,2], but most patients with severe PAH at
the time of their diagnosis have persistent structural alter-
ations of their microscopically small pulmonary arteri-
oles, i.e., pulmonary vascular remodeling believed to be
caused by angiogenic proliferation of endothelial cells
(EC) [3-6]. Complex pulmonary vascular lesions at sites
of bifurcations that are often glomeruloid appearing and
lumen obliterating, including the so-called plexiform
lesions, are frequently found in the lungs of patients with
severe PAH, including the lungs from patients with Eisen-
menger physiology where the lung vessels are subjected to
increased (shunt) blood flow [7]. Whether these complex
vascular lesions can fully explain the PAH remains contro-
versial.
In this article, we review pathogenetic concepts of severe
PAH and explain the term "complex vascular lesion,"
commonly named "plexiform lesion," with EC dysfunc-
tion, i.e., apoptosis, proliferation, interaction with
smooth muscle cells (SMC) and transdifferentiation.
Initial EC apoptosis is followed by the 
emergence of apoptosis-resistant 
proliferating EC
Discordant stimulation of EC or an uncontrolled EC
response are common events in many pathologic proc-
esses including atherosclerosis, allograft vasculopathy,
hypertension, congestive heart failure, sepsis and inflam-
matory syndromes, and PAH [8]. These diseases have in
common endothelial injury, which can result in EC apop-
tosis, dysfunction and activation [8].
Especially pulmonary endothelial injury caused by toxins
[9], reactive oxygen species [10,11], autoimmune mecha-
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nisms [5], and shear stress[12,13] likely leads to severe
PAH.
A recent study showed that bone morphogenic proteins
(BMP) signaling reduced apoptosis of cultured pulmo-
nary artery EC under conditions of serum deprivation and
maintained the survival of cultured circulating endothe-
lial progenitors from normal individuals but not from
IPAH patients. These results support the hypothesis that
loss-of-function mutations in the bone morphogenic pro-
tein receptor II (BMPRII) could lead to increased pulmo-
nary EC apoptosis, representing a possible initiating
mechanism in the pathogenesis of PAH [14].
Taraseviciene-Stewart et al recently described that block-
ade of EC growth factor receptors resulted in the potenti-
ation of PAH and marked worsening of the pathological
vascular remodeling, even reproducing some of the "angi-
oproliferative" features typical of advanced PAH and this
effect was reversed by inhibitors of apoptosis, suggesting
that increased apoptosis of EC in response to loss of sur-
vival signaling created conditions favoring the emergence
of apoptosis-resistant cells with increased growth poten-
tial [15]. Moreover, Campbell et al and Zhao et al have
shown that overexpression of EC growth and survival fac-
tors, such as vascular endothelial growth factor (VEGF)
and angiopoietin-1, prevented the development of
monocrotaline-induced PAH [16,17], an effect that was
associated with reduced EC apoptosis. Together, the find-
ings suggest that EC growth and the emergence of pheno-
typically altered vascular cells in severe PAH is the
consequence of initial apoptosis and subsequent selection
of apoptosis-resistant, proliferative vascular cells. This
concept is consistent with recent finding describing the
absence of apoptotic cells in the plexiform lesions in the
lungs from patients with severe PAH [12] as well as reduc-
tion of severe PAH in the rat model [15] by treatment with
simvastatin, which induced apoptosis of the EC that had
obliterated the pulmonary arterioles [18].
To study the dependence of exuberant EC proliferation on
initial apoptosis, we adapted the CELLMAX artificial cap-
illary system to analyze the effects of the VEGF receptor
(VEGFR) I and VEGFR II antagonist (SU5416) on human
pulmonary microvascular EC (HPMVEC) under condi-
tions of pulsatile shear stress [19].
The experiments with human pulmonary microvascular
EC (HPMVEC) seeded in the artificial capillary system
demonstrated that a combined VEGF I and II receptor
blocker (SU5416) induces EC apoptosis [19]. When this
VEGF receptor blockade-induced apoptosis was followed
by high fluid shear stress a hyperproliferative state was
generated, and within 7 days phenotypically altered EC
emerged [19]. These altered EC expressed the tumor
marker survivin and the antiapoptotic protein Bcl-XL and
were resistant to induction of apoptosis after challenge
with TNF-α plus cycloheximide or hydrogen peroxide; in
addition, the cells demonstrated survival in serum-free
culture medium (Figure 1) [19].
Taken together our data reflect the paradox that growth
factor-inhibition fosters the emergence of apoptosis-
resistant and hyperproliferative cells [19]. This paradox
has recently been described by Golpon et al [20] in exper-
iments which resulted in the conclusion that there is "life
after corpse engulfment". In these experiments it was
shown that cells with apoptosis induced by UV irradia-
tion, after they had been phagocytosed by other cells,
released growth factors into the culture medium and that
this conditioned medium made naïve epithelial- or
endothelial cells apoptosis-resistant [20].
Whether in our shear stress experiments the SU5416
treated apoptotic cells were phagocytosed by neighboring
cells of the CELLMAX system was not examined. In prin-
ciple most cell types (not only professional phagocytes
like macrophages) have the ability to phagocytose apop-
tosed cells [21-24] and we consider this possibility. It is
unclear why the VEGF receptor blockade does not induce
apoptosis in all of the EC and whether the surviving cells
do so because they respond to survival signals which may
be released by the dying cells. Alternatively or additionally
The CELLMAX artificial capillary modules and sequence of events that leads from initial apoptosis to prolif ration of apop osis-resist n  endothe i l cellsFigure 1
The CELLMAX artificial capillary modules and 
sequence of events that leads from initial apoptosis 
to proliferation of apoptosis-resistant endothelial 
cells. The combination of initial apoptosis induced by VEGF 
receptor blockade and high fluid shear stress generates apop-
tosis-resistant proliferative endothelial cells. Definition of 
abbreviations: HPMVEC = human pulmonary microvascular 
endothelial cell; VEGF = vascular endothelial growth factor; 
SU5416 = a combined VEGF I and II receptor blocker.
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it is conceivable that the EC contain some apoptosis-
resistant precursor cells which expand under the condi-
tions of our experiments [19]. Because VEGF receptor inhi-
bition allows apoptosis-resistant EC growth and because
Partovian et al showed that adenovirus-mediated VEGF
over-expression reduced pulmonary hypertension [25] it
is not clear that VEGF causes the angiogenic growth of the
lumen-obliterating EC. It is possible that over-expression
of the VEGF and VEGFR II proteins in the human pulmo-
nary vascular lesions is a reflection of a vascular repair
attempt. Again, the presence of VEGF and VEGFR II in the
vascular lesions does not necessarily mean that VEGF
actually causes the growth of the phenotypically altered
and apoptosis-resistant cells.
Consistent with the result in this in vitro experiment, Masri
and colleagues have reported ex vivo that pulmonary artery
EC (PAECs) isolated from patients with idiopathic PAH
(IPAH) exhibit an unusual hyperproliferative potential,
with decreased susceptibility to apoptosis [26]. Together
with accumulating evidence from previous studies
[15,19,27], this study again provides support for the con-
cept of an apoptosis-resistant and hyperproliferative EC in
IPAH.
The above described in vitro experimental model appears
to support the concept that apoptosis-resistant hyperpro-
liferative EC can emerge at shear stress sensitive sites in the
lung circulation in severe PAH. Although we do not
address experimentally the factor or factors which confer
apoptosis-resistance and phenotypical alterations of a
subpopulation of endothelial stem-like cells, we suggest
that blockade of the signal transduction of the obligatory
EC survival factor, VEGF, in combination with high shear
provide a selection pressure. The nature of the surviving
and proliferating cells remains unclear. It is possible, as
stated above, that the surviving and proliferating cells are
precursor cells [28,29].
Cross talk between endothelial and smooth muscle cells
The interactions of EC and SMC, which exist in the close
contact of a functional syncytium, are involved in a proc-
ess of new vessels formation that occurs during develop-
ment, as part of wound repair, and during the
reproductive cycle. One basic component of this interac-
tion is the endothelial-induced recruitment, proliferation
and subsequent differentiation of SMC [30-32].
Moreover, it was shown in in vitro studies that several
growth factors or cytokines, such as activated transform-
ing growth factor-β1 (TGF-β1) and IL-1β, had been pro-
duced by the EC and SMC in coculture and they might be
involved in some of the effects exerted by the coculture on
these cells [31,33,34]. TGF-β1 is a growth factor which is a
potent stimulant of extracellular matrix synthesis and
inhibits matrix degradation [35]. TGF-β1 has been shown
to potentiate the development of intimal hyperplasia in
animal models following arterial injury [36]. Thus, TGF-
β1 appears to be an important mediator of the increased
extracellular matrix deposition which occurs during vas-
cular wall remodeling. IL-1β is one of inflammatory
cytokines and its elevated serum levels in PAH have been
reported [37].
Theories concerning the detailed pathobiology of PAH
have focused on factors produced by EC and SMC and
their response to different mediators. Prostacyclin (PGI2),
a protein produced by EC and whose known target is
SMC, could be one of the vasodilators. In patients with
PAH, the levels of PGI2 are reduced [38]. Prostacyclin
modulates the vasodilator response of SMC in the case of
acute hypoxia [39].
We have previously hypothesized that the development of
severe angioproliferative PAH is associated with initial EC
apoptosis followed by the emergence of apoptosis-resist-
ant proliferating EC [19]. However, the precise control of
the balance between pulmonary arterial SMC (PASMC)
proliferation and apoptosis is important in maintaining
the structural and functional integrity of the pulmonary
vasculature. In severe angioproliferative PAH, this balance
seems to be disturbed such that there is increased PASMC
proliferation and decreased apoptosis, leading to vessel
wall thickening and vascular remodeling, i.e., hyperplasia
of PASMC [40-43]. Indeed, severe angioproliferative PAH
is characterized by complex precapillary arteriolar lesions
[7,44-46], which contain phenotypically altered endothe-
lial and smooth muscle cells [7]. Interestingly acquisition
of resistance to apoptosis and increased rates of prolifera-
tion of PASMC appear to be necessary for neointima for-
mation [47-52]. This phenotype plasticity, the
dedifferentiation of mature, nonproliferative PASMC into
proliferative PASMC, is a process central to vascular
remodeling [53,54].
We have previously demonstrated that EC death results in
the selection of an apoptosis-resistant, proliferating and
phenotypically altered EC phenotype [19]. Therefore we
postulated that the initial apoptosis of EC induced the
release of mediators which caused VSMC proliferation. To
study this hypothesis, apoptosis of microvascular EC was
induced by VEGF receptor blockade using the combined
VEGFR-I and II blocker SU5416 and it was shown that
serum-free medium conditioned by apoptosed EC caused
proliferation of vascular SMC compared with serum-free
medium conditioned by non-apoptosed EC [55]. It was
also shown that serum-free medium conditioned by
apoptosed EC is characterized by increased concentra-
tions of TGF-β1 and VEGF compared with serum-free
medium conditioned by non-apoptosed EC, and that
Respiratory Research 2009, 10:95 http://respiratory-research.com/content/10/1/95
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TGF-β1 blockade prevented the proliferation of cultured
vascular SMC [55]. In conclusion, EC death induced by
VEGF receptor blockade leads to the production of factors,
in particular TGF-β1, which activates vascular SMC prolif-
eration, i.e., that EC apoptosis may stimulate vascular
SMC growth (Figure 2) [55].
Moreover, several recent studies showed that EC seeding
of injured arterial wall segments appears to limit the SMC
response to injury. It was shown that EC seeding of endar-
terectomized canine arteries decreased the intimal hyper-
plastic response [56] and that EC seeding of injured
hypercholesterolemic rabbit femoral arteries also limits
the intimal hyperplastic response [57]. It is, therefore, rea-
sonable to hypothesize that apoptosed EC may lose their
control over SMC allowing SMC growth.
Recent studies suggest that, in response to intimal injury,
synthetic/proliferative SMC migrated to the intima can
generate proinflammatory molecules to promote WBC
infiltration of the artery wall [53,58,59]. EC injury caused
by proinflammatory molecules may lead to EC apoptosis
and SMC growth and thus a EC apoptosis-SMC growth
loop could result in the progression of PAH.
It is likely that dysregulated growth factors or cytokines
produced by EC and SMC exert autocrine or paracrine
effects which contribute to the progression of remodeling
in pulmonary artery that results in PAH.
Endothelial-Mesenchymal transdifferentiation
Transdifferentiation is a form of metaplasia and the con-
version of one differentiated cell type into another, with
or without intervening cell division, so this mechanism
challenges the preconceived ideas that the terminal differ-
entiated state is fixed. Indeed, it is now generally accepted
that "differentiation" can sometimes be reversed or
altered [60].
In the neointima formation and vascular remodeling
fibroblasts in the pulmonary vascular wall play specific
roles in the response to injury, including rapid migration,
proliferation, synthesis of connective tissue, contraction,
cytokine production, and, most importantly, transdiffer-
entiation into other types of cells (e.g., PASMC) [61].
Hypoxia-induced changes in fibroblasts' proliferative and
matrix-producing phenotypes are accompanied by the
appearance of smooth muscle α-actin in tissues from pul-
monary hypertensive subjects, suggesting that some of the
fibroblasts transdifferentiate into myofibroblasts [62].
This transdifferentiation involves a complex network of
microenvironmental factors and pathways in which extra-
cellular matrix components as well as growth factors,
cytokines, and adhesion molecules may play a role [63].
The intriguing possibility that intimal SMC may arise
from the endothelium has received some attention
[64,65]. In the systemic circulation, Arciniegas et al
showed that mesenchymal cells that contribute to the inti-
mal thickening may arise from the endothelium by using
in vivo and in vitro methods [66].
Severe angioproliferative PAH is characterized by complex
pulmonary precapillary arteriolar lesions [7,44-46],
which contain phenotypically altered SMC and EC [7]. In
addition to lumen-obliterating cell aggregates, which
form the so-called plexiform lesions, muscularized arter-
ies are also frequently present. Vasoconstriction as well as
peptide (endothelin and angiotensin II) and nonpeptide
(serotonin) growth factors have been postulated to be
responsible for the muscularization of the pulmonary
arteries in severe PAH [67-69]. Indeed "transitional cells"
demonstrating features of both EC and vascular SMC have
been identified in the plexiform lesions in the lungs from
patients with severe angioproliferative PAH [70]. We
hypothesize that an additional or alternative mechanism
contributing to the muscularization of the pulmonary
arteries may be transdifferentiation of pulmonary EC to
mesenchymal cells.
Sequence of events that leads from SU-5416-induced VEGF blockade t  the increased growth of VSMCFig re 2
Sequence of events that leads from SU-5416-induced 
VEGF blockade to the increased growth of VSMC. 
VEGF receptor blockade induces apoptosis of vascular 
endothelial cells. Apoptotic endothelial cells release growth 
factors such as VEGF and TGF-β1, and, whereas VEGF inhib-
its apoptosis, TGF-β1 promotes VSMC proliferation. Defini-
tion of abbreviations: HPMVEC = human pulmonary 
microvascular endothelial cell; VSMC = vascular smooth 
muscle cell; TGF-β1 = transforming growth factor-β1; VEGF = 
vascular endothelial growth factor; SU5416 = a combined 
VEGF I and II receptor blocker.
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To examine this hypothesis, we incubated HPMVEC with
SU5416 and analyzed these cells utilizing quantitative-
PCR, immunofluorescent staining and flow cytometry
analysis [71]. In vitro studies of HPMVEC demonstrated
that SU5416 suppressed PGI2S gene expression while
potently inducing COX-2, VEGF and TGF-β1 expression,
causing transdifferentiation of mature vascular EC
(defined by Dil-ac-LDL, Lectin and Factor VIII) into SM-
like (as defined by expression of α-SM actin) "transi-
tional" cells, which coexpressed both endothelial and SM
markers [71]. In this experiment, the SU5416-induced
transdifferentiation was independent of TGF-β1 [71].
Although TGF-β1 was shown to be involved in inducing
endothelial-mesenchymal transdifferentiation [72] and is
known to promote SM-actin expression in nonmuscle
cells (EC and fibroblasts derived from various tissues)
[73,74], TGF-β1 is currently thought to be insufficient to
induce expression of late SM differentiation marker SM
myosin heavy chain (SM-MHC) in non-SMC lineage cells
[74]. SU5416 expanded the number of CD34 and/or c-kit
positive cells and caused transdifferentiation of CD34+
cells, but not CD34- cells. In conclusion, this data showed
that SU5416 generated a selection pressure that killed
some EC and expanded resident progenitor-like cells to
transdifferentiate into SM like cells (Figure 3) [71]. Fur-
ther, we fully realize the limitation of our data interpreta-
tion which is based on in vitro studies of cultured cells.
However, we believe that our data may be consistent with
the concept that transdifferentiation of pulmonary EC to
mesenchymal cells may contribute to the muscularization
of the pulmonary arteries.
The prevailing theory of the vascular SMC contribution to
vascular lesions is that in pathological states, like athero-
sclerosis, SMCs migrate to the intima from the media of
the vessel [75]. This concept, however, has been chal-
lenged by results derived from models of vascular injury,
transplant arteriosclerosis, and human allograft studies,
which all indicate that a portion of the cells bearing SMC
differentiation markers in intimal lesions may have origi-
nated from the hematopoietic system and/or circulating
progenitor cells [76-78]. Furthermore, a recent study dem-
onstrated that smooth muscle progenitors were present in
circulating blood [79], although the origin of these cells
remains unknown. Concomitantly, it was shown that ~
60% of SMC in atherosclerotic lesions of vein grafts were
derived from the donor vessel wall and 40% from the
recipient, possibly from circulating blood cells [80,81]. In
the aggregate these reports strongly suggest the possibility
of stem or progenitor cells as a source of SMC accumula-
tion in atherosclerotic lesions. However, not all of the
SMC within intimal lesions may be derived from bone
marrow cells. Recently it was shown that, in addition to
circulating progenitor cells, Sca-1+ progenitor cells that
reside in the adventitia can transdifferentiate into SMC-
like neointimal cells [82], suggesting that not only bone
marrow cells but also resident vessel wall precursor cells
could exist and serve as a source of SMC to form neointi-
mal lesions.
Ingram and colleagues [29] have resolved progenitor cells
within a population of EC isolated from conduit vessels in
the systemic circulation. These findings suggest that EC
isolated from the vessel wall are enriched with progenitor
cells that rapidly proliferate and can renew the entire pop-
ulation. This report confirms the unexpected finding in
our study [71] that there is the presence of a small number
of bone marrow-derived c-kit+, CD34+ endothelial precur-
sor cells among various batches of commercially available
lung microvascular EC, suggesting the presence of such
precursor cells in the adult lung.
The greater context of these findings, i.e., residential
endothelial precursor cells and their transdifferentiation,
may be a general mechanism for muscularization of ves-
sels and, in the nondeveloping adult lung, a mechanism
which participates in lung tissue homeostasis and repair
of injured lung cells via utilization of resident lung tissue
precursor cells.
Sequence of events in HPMVEC that lead from VEGF block-ade by SU5416 to transdifferentiation to sm oth muscle-li e c llsFig re 3
Sequence of events in HPMVEC that lead from VEGF 
blockade by SU5416 to transdifferentiation to 
smooth muscle-like cells. Endothelial cell death induced 
by VEGF receptor blockade and subsequent selection of pro-
genitor-like cells leads to transdifferentiation to smooth mus-
cle-like cells and neuronal cell. Dotted arrows mean 
hypothetical sequences of events. Definition of abbreviations: 
HPMVEC = human pulmonary microvascular endothelial cell; 
VSMC = vascular smooth muscle cell; SU5416 = a combined 
VEGF I and II receptor blocker.
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Genetic and/or epigenetic factors in PAH - a perspective
Genetic mutations, like BMPRII mutations that have been
found in patients with familial and nonfamilial forms of
IPAH [83], may contribute to cell growth control. Indeed,
there is a growing literature that associates BMP and their
receptors with cell growth control, even in cancers [84-
86].
Not only somatic cell mutations may contribute to the
hyperproliferative, apoptosis-resistant endothelium phe-
notype, but the unusual EC phenotype could also arise
from a normal resident or itinerant lung cell population
as a result of genomic events [71,87].
Not only "genetic", but also "epigenetic factors", should
be considered as factors or conditions which induce the
hyperproliferative, apoptosis-resistant endothelium phe-
notype. Epigenetics, here understood as a bridge between
genotype and phenotype, can influence gene expression
without changing the underlying DNA sequence, i.e., epi-
genetic modifications can express themselves via DNA
methylation and histone modifications [88-91]. Dietary
and hormonal influence can be envisioned to affect the
pulmonary vessels in patients with IPAH, initiating or
amplifying changes in the EC residing along the pulmo-
nary vessels [92,93].
It is hypothesized that apoptosis-resistant, phenotypically
altered and transdifferentiated EC may arise by genetic
and epigenetic mechanisms.
Conclusion
It is tempting to speculate in the context of PAH that fol-
lowing EC apoptosis a selection of cells characterized by a
high proliferative potential, including resident progenitor
cells, results in a prevalence of hyperproliferative, apopto-
sis-resistant pulmonary vascular lesion cells that contrib-
ute to the irreversible and progressive nature which
characterizes many forms of severe PAH (Figure 4).
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